

## Cr<sup>VI</sup> exposure and biomarkers: Cr in erythrocytes in relation to exposure and polymorphisms of genes encoding anion transport proteins

QINGSHAN QU<sup>1</sup>, XIAOMEI LI<sup>1</sup>, FEIYUN AN<sup>2</sup>, GUANG JIA<sup>3</sup>, LANZENG LIU<sup>4</sup>, HIROKO WATANABE-MESERVE<sup>1</sup>, KAREN KOENIG<sup>1</sup>, BEVERLY COHEN<sup>1</sup>, MAX COSTA<sup>1</sup>, NIRMAL ROY<sup>1</sup>, MIANHUA ZHONG<sup>1</sup>, LUNG CHI CHEN<sup>1</sup>, SUHUA LIU<sup>4</sup>, & LEI YAN<sup>3</sup>

<sup>1</sup>Nelson Institute of Environmental Medicine, New York University School of Medicine Tuxedo, New York 10987, USA, <sup>2</sup>Department of Toxicology, Central South University School of Public Health, Changsha, Hunan 410078, China, <sup>3</sup>Department of Environmental and Occupational Health, Peking University School of Public Health, Beijing 100083, China and <sup>4</sup>Jinan Municipal Center for Disease Control and Prevention, Jinan, Shandong 250013, China

### Abstract

A total of 195 subjects, including 141 exposed workers and 54 farmers, were recruited in China to evaluate the usefulness of chromium (Cr) in erythrocytes as a biomarker of exposure to Cr<sup>VI</sup>. The levels of Cr in red blood cells (RBC) were remarkably elevated even in a group of workers routinely exposed to Cr<sup>VI</sup> as low as 5–15 µg m<sup>-3</sup> and showed a significant exposure–response trend over the exposure range from 0.002 to 1152 µg m<sup>-3</sup> ( $p < 0.0001$ ). Multiple linear regression analyses indicated that age and cigarette smoke were not associated with Cr in RBC. However, female subjects had lower Cr in RBC compared with their male counterparts for about the same exposure levels ( $p < 0.05$ ). The genotypes of band III, which encodes for anion transport protein and may regulate CrO<sub>4</sub><sup>-2</sup> across cell membranes, were also identified and included for analysis. The ratios of Cr in RBC to Cr<sup>VI</sup> exposure were higher in subjects with a wild genotype than in those who had heterozygous or homozygous variant alleles. However, the difference was not statistically significant probably due to the limited number of participating subjects. In addition, 15 of the 141 workers were selected for multiple exposure monitoring and blood sample collections to evaluate the inter- and intraindividual variations of Cr in RBC. Compared with the personal exposure levels, Cr in RBC had small intraindividual variations with a reliability coefficient of 0.88. The study suggests that Cr in RBC may serve as a sensitive and reliable biomarker for long-term exposure to Cr<sup>VI</sup>.

(Received 8 October 2007; accepted 4 April 2008)

### Introduction

Chromium (Cr) is a generally abundant element in the earth's crust and occurs in oxidation states ranging from Cr<sup>2+</sup> to Cr<sup>6+</sup>, but only trivalent (Cr<sup>III</sup>) and hexavalent (Cr<sup>VI</sup>) forms are of biological significance. Cr<sup>III</sup>, the more common form, is known to

---

Correspondence: Qingshan Qu, Nelson Institute of Environmental Medicine, New York University School of Medicine, 57 Old Forge Road, Tuxedo, NY10987, USA. E-mail: qingshan@env.med.nyu.edu

ISSN 1354-750X print/ISSN 1366-5804 online © 2008 Informa UK Ltd.  
DOI: 10.1080/13547500802099574

be essential for certain physiological functions and does not show significant health hazard to humans partly due to its poor absorption and inability to cross cell membranes (NRC 1989, Anderson 1994, Costa 1997). In contrast,  $\text{Cr}^{\text{VI}}$  is a strong oxidizing agent and poses much greater human health hazards than its trivalent analogue.  $\text{Cr}^{\text{VI}}$  has been consistently associated with increased mortality due to respiratory cancer in numerous studies of workers with occupational exposures, and therefore, is recognized as a human carcinogen (IARC 1990, Moulin et al. 1990, Davies et al. 1991, Wang et al. 1994, De Flora 2000).  $\text{Cr}^{\text{VI}}$  is present in most of the Superfund toxic waste dump sites and has been known as a widespread environmental contaminant; therefore, its potential toxic and carcinogenic effects at ambient levels on humans have attracted increasing public concern.

Monitoring of Cr in different biological matrices, such as urine, plasma, erythrocytes, lymphocytes and exhaled breath condensate, etc. has been used as a biomarker of Cr exposure (McAughy et al. 1988, Minoia et al. 1988, Lukanova et al. 1996, Miksche & Lewalter 1997, Caglieri et al. 2006, Murgia et al. 2006). Unlike many other metals,  $\text{Cr}^{\text{VI}}$  exhibits some chemical properties that significantly affect its bioavailability in cells. As indicated in a recent review,  $\text{Cr}^{\text{VI}}$  readily crosses the cell membrane as a tetrahedral divalent  $\text{CrO}_4^{2-}$  anion, which is structurally similar to  $\text{SO}_4^{2-}$  and  $\text{PO}_4^{3-}$  anions, and therefore may share with them the same anion transport carrier identified as a band III protein (Chiu et al. 2004). Band III is a member of a widely distributed family of proteins present in many tissues. They play important roles in many cellular processes that involve the exchange transport of anions across membranes (Alper 1991, Bruce & Tanner 1999). Once entering into cells via band III-regulated uptake,  $\text{Cr}^{\text{VI}}$  is reduced quickly through several steps into  $\text{Cr}^{\text{III}}$ , which forms octahedral complexes and is trapped inside the cells because it typically crosses cell membranes by simple diffusion at a rate three orders of magnitude lower than  $\text{Cr}^{\text{VI}}$  (Cohen et al. 1993, Chiu et al. 2004). Intracellular reduction and trapping of reduced Cr appear to be important determinants of accumulation of chromate in cells, and therefore, intracellular Cr has been proposed as an indicator of  $\text{Cr}^{\text{VI}}$  exposure (Cohen et al. 1993, Alexander & Aaseth 1995). The present study was conducted in a Chinese population with a broad range of  $\text{Cr}^{\text{VI}}$  exposure to examine the usefulness of Cr in erythrocytes as an exposure biomarker for  $\text{Cr}^{\text{VI}}$ . The study also examines the potential effects of band III polymorphism on Cr in erythrocytes.

## Materials and methods

The human subject protocol for this study was approved by the IRBs of both the New York University School of Medicine and the Central South University School of Public Health in China. Written informed consent was obtained from all participating subjects.

### *Subject recruitment and personal exposure monitoring of $\text{Cr}^{\text{VI}}$*

A total of 195 subjects were recruited through questionnaire interview, physical examination and personal exposure monitoring for  $\text{Cr}^{\text{VI}}$ . These included 141 workers from a chromate factory, in which sodium dichromate ( $\text{Na}_2\text{Cr}_2\text{O}_7$ ) was used as a raw material to produce chromic anhydride ( $\text{CrO}_3$ ), and 54 farmers recruited from an area about 90 miles away from the chromate facility in Shandong, China. A full-shift (8 h)

personal-exposure sample was collected for each individual subject onto a 0.8 µm mixed cellulose ester (MCE) filter. A small personal pump drew air through the lapel-mounted filter holder at 2 l min<sup>-1</sup>. For quality control purposes, both blank and spiked monitors (10% of the total samples) were also prepared in the field. At the end of personal-exposure monitoring, all subjects were asked to provide 50 ml urine samples. Each sample was collected in a sterile specimen container and then an aliquot was transferred into a 15 ml cell culture centrifuge tube. These aliquots of urine samples were kept at 4°C after collection in the field and during transportation to a local laboratory. All urine samples were then stored at -20°C until analysed for cotinine and creatinine. In addition, a 5 ml blood sample was collected into a heparinized Vacutainer tube from each of the participating subjects by a local registered nurse.

NIOSH method 7600 was employed to determine Cr<sup>VI</sup> sampled on the filters (Eller & Cassinelli 1994). The recovery rate of Cr<sup>VI</sup> from the filters spiked with K<sub>2</sub>CrO<sub>4</sub> standards was 92.1 ± 3.0%. The limit of detection was 0.06 µg per filter as estimated based on the measurement of 10 blank filters (mean + 3 SD of blank filters). The concentration (C) of Cr<sup>VI</sup> in air was calculated by the following equation:

$$C (\mu\text{g}/\text{m}^3) = [W (\mu\text{g}) - B (\mu\text{g})]/V (\text{m}^3)$$

where W and B are mass of Cr<sup>VI</sup> in each sample and average blank, respectively. V is the total air volume sampled.

#### *Blood sample preparation and analysis of Cr in red blood cells*

Red blood cells (RBC) were separated and prepared according to the method described by Lukanova et al. (1996). Briefly, haematocrit 1 (Ht 1) was first determined soon after collection, using a haematocrit centrifuge. Samples were then left for 30–40 min at room temperature to allow the blood to separate into two fractions: fraction 1, the supernatant, contained the plasma and white blood cells, and fraction 2 the residual, contained predominantly red blood cells. The interphase between the two fractions, containing mainly the lymphocytes, was transferred into cryogenic vials and stored at -70°C for DNA isolation and genotype identification. The second fraction was resuspended with 0.9% sodium chloride up to the initial volume of blood collected, allowed to stand at room temperature for 10 min, and centrifuged for 10 min at 3000 rpm. The same washing procedure was repeated twice more with 0.9% NS. Haematocrit 2 measurement (Ht 2) and RBC counts were made just before centrifuging for the last washing. The erythrocyte pellet after the last wash was diluted to the final volume of the blood sample with Triton X-100 at 0.1%. The lysed RBC preparations were then ready to use for Cr analysis.

Cr levels in erythrocytes were measured by graphite furnace atomic absorption with Zeeman background correction as described by Gao et al. (1993) using a Thermo Elemental Solaar M6 atomic absorption spectrometer. Reference standard solution (potassium dichromate) certified by Fisher was used to make a series standards for calculation. The limit of detection in this study was 0.3 µg l<sup>-1</sup>. To investigate any error inherent in the procedures of RBC preparation and Cr analysis, we identified one subject who agreed to provide one single donation of 25 ml of blood samples (collected in five separate Vacutainer tubes). These tubes of blood, serving as quality control (QC) samples, were coded to appear like regular study samples so that those

performing the RBC preparations and analyses of Cr were not aware of the nature of these QC samples. The coefficient of variation (CV) for Cr levels in erythrocytes of these QC samples was 12.9%.

#### *DNA isolation and genotype identification of band III gene*

DNA was isolated from blood samples using the commercial QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA).

*Band III polymorphism (band III Memphis) at codon 56.* Human erythrocyte band III polymorphism of Lys56Glu was identified by using allele-specific probes in real-time polymerase chain reaction (PCR). Primers and probes were designed using PrimerExpress 3.0 software (Applied Biosystems, Foster City, CA, USA). The primers were: 5'-CACAGACTACCACACCACATCACA-3' (forward) and 5'-AAAGGCAGCATGGGAAAGAA-3' (reverse). 5'-<sup>VIC</sup>ACCCACGAGGTGAG<sup>MGB</sup>-3' and 5'-<sup>FAM</sup>ACCCACAAGGTGAGG<sup>MGB</sup>-3' were used as specific probes for A and G alleles, respectively. Reactions were performed using the Applied Biosystems 7300 real-time PCR instrument in 96-well plates with each well containing 20 ng of genomic DNA isolated from blood, 1 × TaqMan master mix, dual-labelled probes (100 nM each) and PCR primers (900 nM each). Each plate contained two control DNA samples for each homozygous genotype and four no template controls. In addition, 10% of samples were repeated for quality control purpose.

#### *Measurement of urinary cotinine and creatinine*

Urinary cotinine, one of the major metabolites of nicotine, was employed to evaluate the smoking status of study subjects and was quantified by cotinine direct enzyme-linked immunosorbent (ELISA) kits (Immunalysis, Pomona, CA, USA). In order to adjust the levels of cotinine in urine samples, urinary creatinine was also determined using commercially available creatinine assay kits according to the standard procedure provided (ThermoDMA, Arlington, TX, USA).

#### *Statistical analyses*

For statistical analyses, log transformation was performed on levels of Cr in both RBC and air to improve the normality. Differences in the levels of Cr in RBC among groups were compared by two-sample Student's *t* test. The levels of Cr in RBC and Cr<sup>VI</sup> exposure among non-smokers, moderate smokers and heavy smokers in participating farmers were compared using ANOVA. The multiple linear regression analysis was used to evaluate the impact of Cr<sup>VI</sup> exposure on Cr in RBC while controlling potential confounders such as age, gender, cotinine levels and genotypes of band III. The data were analysed using SAS statistical packages (SAS Institute Inc., Cary, NC, USA). All the *p* values were two-sided.

## **Results**

The demographic characteristics of the participating subjects and the levels of their personal exposure to Cr<sup>VI</sup> monitored on the day of biological sample collections are shown in Table I. Both self-reported data on smoking habits and urinary cotinine

Table I. Characteristics of the study subjects, exposure levels and Cr in red blood cells (RBC).

	Workers (n = 141)	Farmers (n = 54)	p-Values
Female, n (%)	39 (27.7)	11 (20.4)	0.30
Smoking (cotinine >100 µg g <sup>-1</sup> creatinine), n (%)	66 (46.8)	33 (61.1)	0.076
Age (years), median (1st and 3rd quartiles)	35 (31, 41)	34 (30, 39)	0.23
Cr <sup>VI</sup> exposure (µg m <sup>-3</sup> ), median (1st and 3rd quartiles)	17.8 (6.8, 46.3)	0.06 (0.01, 0.13)	0.001
Cr in RBC (µg l <sup>-1</sup> ), median (1st and 3rd quartiles)	6.00 (3.75, 11.61)	2.64 (1.44, 3.55)	<0.0001

levels were initially used to discriminate smokers from non-smokers. It was observed that all self-reported smokers had elevated cotinine levels ( $\geq 100 \mu\text{g g}^{-1}$  creatinine). On the other hand, almost all non-smokers were found to have cotinine levels far below  $100 \mu\text{g g}^{-1}$  creatinine, except three farmers with levels slightly higher than  $100 \mu\text{g g}^{-1}$  creatinine. Therefore, a cotinine level of  $100 \mu\text{g g}^{-1}$  creatinine was used as criteria to affirm smoking status. As shown in Table I, there were no significant differences in age, sex and smoking status between the two groups. The median exposure levels of Cr<sup>VI</sup> monitored in the participating workers and farmers on the day of biological sample collections were  $17.8 \mu\text{g m}^{-3}$  and  $0.06 \mu\text{g m}^{-3}$ , respectively. Accordingly, the levels of Cr in RBC in workers were significantly higher than those in the participating farmers ( $p < 0.0001$ ). To evaluate the sensitivity of Cr in RBC as a biomarker for Cr<sup>VI</sup> exposure, the study subjects were further divided into six subgroups according to their exposure levels of Cr<sup>VI</sup>. As shown in Figure 1, the geometric means of Cr in RBC increased significantly in groups of workers exposed to Cr<sup>VI</sup> at or above  $5 \mu\text{g m}^{-3}$  and showed a significant exposure-response trend over the entire exposure range from 0.002 to  $1152 \mu\text{g m}^{-3}$  ( $p < 0.0001$ ).

In order to examine the effects of confounding factors including smoking and other demographic factors, such as age and sex, on the levels of Cr in RBC, an initial analysis was first conducted to compare the levels of Cr in RBC among non-smokers, moderate smokers and heavy smokers in the recruited farmers. As shown in Table II, no significant difference was detected in the levels of Cr in RBC between smokers and non-smokers. Furthermore, multiple regression analyses of Cr in RBC were conducted on Cr<sup>VI</sup> exposure in all recruited subjects, controlling for age, gender and smoking as possible confounders. The results indicated that age and cigarette




Figure 1. Relationship between Cr<sup>VI</sup> exposure and the levels of Cr in red blood cells (RBC) (geometric mean and SD). The number shown in the columns represents the subject number in corresponding subgroup. \*Compared with farmers,  $p < 0.0001$ ; \*\*exposure-response trend test,  $p < 0.0001$ .

Table II. Effects of cigarette smoking intensity on the levels of Cr in red blood cells (RBC). Values are median (1st quartile, 3rd quartile).

Groups <sup>a</sup>	No. of subjects	Cr exposure ( $\mu\text{g m}^{-3}$ )	Cr in RBC ( $\mu\text{g l}^{-1}$ )
Non-smokers	21	0.06 (0.02, 0.14)	2.70 (1.76, 3.15)
Moderate smokers	10	0.05 (0.01, 0.08)	3.36 (2.41, 4.30)
Heavy smokers	23	0.05 (0.01, 0.14)	1.84 (1.25, 3.45)

<sup>a</sup>Grouped according to urinary cotinine levels: non-smokers,  $<100 \mu\text{g g}^{-1}$  creatinine; moderate smokers, 100 to  $<1000 \mu\text{g g}^{-1}$  creatinine; heavy smokers,  $\geq 1000 \mu\text{g g}^{-1}$  creatinine.

smoke were not among the confounders. However, female subjects may have lower Cr in RBC compared with male counterparts at about the same exposure levels (Table III,  $p < 0.05$ ).

To evaluate whether or not genetic variations contribute to the difference in individuals' accumulation of Cr in RBC due to  $\text{Cr}^{\text{VI}}$  exposure, the band III Memphis polymorphisms were identified using the real-time PCR technique. The genotype identification demonstrated that there were only three subjects who had homozygous variant alleles. Therefore, the data obtained from subjects who had either heterozygous or homozygous variant alleles were merged together and compared with that from those who had a wild genotype. Because the exposure levels of  $\text{Cr}^{\text{VI}}$  were not comparable between the two genotype groups, it is not appropriate to compare Cr levels in RBC directly. Alternatively, the ratios of Cr in RBC to  $\text{Cr}^{\text{VI}}$  exposure ( $\mu\text{g l}^{-1}$  per  $\mu\text{g m}^{-3}$  of  $\text{Cr}^{\text{VI}}$ ) were calculated and analysed. They were found to be higher in subjects with a wild genotype than that in those with either heterozygous or homozygous variant alleles. However, the differences were not statistically significant in either occupationally or non-occupationally exposed subjects probably due to the limited number of participating subjects (Figure 2). A multiple regression analysis

Table III. Least squares regression analysis relating Cr in red blood cells (RBC) to Cr exposure levels with or without adjustment by sex, smoking, age and band III.

	$\beta$ (SE)	p-Values
<i>Cr exposure only without adjustment</i>		
Ln Cr exposure	0.16 (0.013)	$<0.0001$
<i>Adjusted for sex</i>		
Ln Cr exposure	0.15 (0.013)	$<0.0001$
Sex, female	-0.11 (0.054)	0.042
<i>Adjusted for sex, smoking and age</i>		
Ln Cr exposure	0.15 (0.013)	$<0.0001$
Sex, female	-0.14 (0.063)	0.0309
Log Cotinine	-0.05 (0.054)	0.4127
Age	-0.003 (0.004)	0.4952
<i>Adjusted for sex, smoking, age and band III</i>		
Ln Cr exposure	0.15 (0.013)	$<0.0001$
Sex, female	-0.13 (0.065)	0.0486
Log Cotinine	-0.014 (0.027)	0.6088
Age	-0.003 (0.004)	0.5150
Band III polymorphism	0.003 (0.060)	0.9551






Figure 2. Effects of band III polymorphism on Cr levels in red blood cells (RBC) ( $\mu\text{g l}^{-1}$  per  $\mu\text{g m}^{-3}$  of Cr<sup>VI</sup> exposure). The number shown in the columns represents the subject number in corresponding subgroup.

further suggested that Band III Memphis polymorphism may not significantly affect the transport of Cr<sup>VI</sup> across membranes of erythrocytes (Table III).

In order to examine further the reliability of Cr in RBC to index Cr<sup>VI</sup> exposure, 15 out of the 141 exposed workers were selected for multiple personal exposure monitoring and blood sample collections on three consecutive Mondays to evaluate the inter- and intraindividual variations of Cr in RBC. As shown in Table IV, the variations in personal exposure levels of Cr<sup>VI</sup> were substantially larger within subjects relative to between subjects. Compared with the personal exposure levels, Cr in RBC had relatively small intraindividual variations with reliability coefficient of 0.88, suggesting that Cr in RBC may serve as a sensitive and reliable biomarker for long-term Cr<sup>VI</sup> exposure (Table IV).

## Discussion

As shown in Table I, Cr levels in RBC were significantly higher in exposed workers than in participating farmers ( $p < 0.0001$ ); however, the difference appears to be relatively small compared with the extremely different exposure levels between the two groups. Because Cr may be lost during the process of erythrocyte preparation the validity of the results needs to be addressed. According to the literature, the background levels of Cr in RBC are  $2.5 \pm 1.5 \mu\text{g l}^{-1}$  (mean  $\pm$  SD) and  $4.5 \mu\text{g l}^{-1}$  (mean plus 1 standard error) in control subjects (Kerger et al. 1996, Lukanova et al. 1996). Cr in RBC measured in the participating farmers in the present study is comparable to these reference levels with a median of  $2.64 \mu\text{g l}^{-1}$ . This may suggest

Table IV. Intra- and interindividual variations of Cr in red blood cells (RBC).

	Variance Components		Reliability coefficient (R) <sup>a</sup>
	Between subjects	Within subjects	
Ln Cr in RBC	0.556	0.077	0.88
Ln Cr <sup>VI</sup> exposure	0.641	0.666	0.49

<sup>a</sup>Reliability coefficient (R) =  $\text{Variance}_{\text{Between}} / (\text{Variance}_{\text{Between}} + \text{Variance}_{\text{Within}})$ .

that there was no significant loss or contamination of Cr in samples collected in farmers due to the procedure of RBC preparation. Furthermore, the results of QC sample analyses in this study suggested that there was no significant error inherent in the procedures of RBC preparation and Cr analysis. Any loss of Cr in RBC during preparation should be randomly distributed into samples collected from either exposed or unexposed subjects. It is not likely that a potential loss of Cr due to preparation procedures will contribute only to the measurement of samples collected from exposed subjects. Therefore, based on the outcomes of QC sample analyses and background levels in farmers the Cr levels of RBC in exposed workers should be reliable. This is further supported by the excellent exposure–response relationship as shown in Figure 1.

Cr in RBC has long been recognized as a biomarker to index an integrated Cr<sup>VI</sup> exposure over a lifespan of erythrocytes (approximately 120 days) (Wiegand et al. 1988, Lukanova et al. 1996, Miksche & Lewalter 1997). However, very few studies have been conducted so far to evaluate how well and reliable a single measurement of Cr in RBC reflects the integrated exposure level of Cr<sup>VI</sup> within an individual. For this purpose, the analyses of inter- and intraindividual variations over time with regard to levels of Cr<sup>VI</sup> exposure and Cr in RBC were performed in this study on 15 subjects with data gathered on three consecutive Mondays. As shown in Table IV, the results revealed that the personal exposure levels to Cr<sup>VI</sup> fluctuated greatly within individuals over time and the intraindividual variations were even greater than interindividual variations. Unlike personal exposure monitoring, the levels of Cr in RBC were relatively stable within an individual over time. The within-individual variations of Cr in RBC were small relative to the between-individual variations with reliability coefficient of 0.88. These suggest that a single measurement of Cr in RBC is representative of the average of multiple sample analyses of Cr in RBC, and therefore, it is appropriate and reliable to use one sample measurement per subject to index his/her integrated Cr<sup>VI</sup> exposure.

It has been shown that Cr<sup>VI</sup> is not stable in the bloodstream after absorption due to the presence of various reductants in plasma, such as ascorbic acid and glutathione. As indicated in a number of studies, following exposure, Cr<sup>VI</sup> can reach the bloodstream and is subject to further reduction within plasma, which may prevent Cr<sup>VI</sup> uptake by erythrocytes (Harzdorf & Lewalter 1997, Miksche & Lewalter 1997, Corbett et al. 1998). Harzdorf & Lewalter (1997) investigated an *in vitro* reduction rate of Cr<sup>VI</sup> in plasma and found that Cr<sup>VI</sup> concentration faded gradually after a single exposure and decreased by about 20% within the initial 60 min. This finding may suggest that plasma reductive capacity is not sufficiently strong to prevent Cr<sup>VI</sup> from penetrating into cells, including erythrocytes. Other factors should also be considered as potential confounders when examining confounding effects for Cr uptake by erythrocytes.

Band III is a member of a widely distributed family of proteins present in many tissues, which play important roles in many cellular processes that involve the exchange transport of anions across membranes (Alper 1991, Bruce & Tanner 1999). It was, therefore, proposed that band III proteins may also be important in regulating Cr<sup>VI</sup> transport across membranes of erythrocytes due to the similarity of CrO<sub>4</sub><sup>-2</sup> with SO<sub>4</sub><sup>-2</sup> and PO<sub>4</sub><sup>-3</sup>. The role of band III proteins in modulating Cr<sup>VI</sup> uptake by erythrocytes was first investigated using <sup>51</sup>Cr<sup>VI</sup> in human erythrocytes independently by two groups of researchers (Ottenwaelder et al. 1988, Alexander & Aaseth 1995). Both studies demonstrated that the uptake of <sup>51</sup>Cr<sup>VI</sup> by erythrocytes was fast and



efficient, and could be significantly inhibited by the addition of 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, an established band III protein inhibitor. These findings suggest that Cr<sup>VI</sup> uptake by erythrocytes is indeed dependent on band III activity. However, there has been no study conducted so far to evaluate if the genetic variations of band III account for the observed interindividual difference in cellular uptake of Cr<sup>VI</sup>.

The gene encoding band III protein has been found to be polymorphic. The most common polymorphism is band III Memphis and represents a widespread polymorphism, being detected with a prevalence ranging from 5% to 24% in virtually all ethnic groups with slightly reduced anion transport activity (Palatnik et al. 1990, Jarolim et al. 1992, Bruce et al. 1994, Bruce & Tanner 1999). The present study examined, for the first time, the potential effects of band III Memphis polymorphism on the relationship between Cr in RBC and Cr<sup>VI</sup> exposure in humans. Our data indicate that the ratios of Cr in RBC to Cr<sup>VI</sup> exposure were higher in subjects with the wild genotype than that in those with heterozygous or homozygous variant alleles. However, the differences were not statistically significant probably for two reasons. First, the anion transport activity is only slightly reduced in subjects with variant alleles compared with those with wild genotype. As a result, detection of the weak effect of variant genotype may need a relatively large number of subjects. In fact, the number of subjects who have either heterozygous or homozygous alleles is only 27 and 10 in exposed workers and farmers, respectively. Obviously, a further study with relatively large number of subjects, especially those who have homozygous alleles, is needed in order to reach a firm conclusion.

The monitoring of Cr in urine provides a useful measure of internal Cr exposure and has been used in the workplace to assess short-term high-level exposures to Cr<sup>VI</sup>. However, urinary Cr mainly reflects the most current exposure and is not predictive for integrated or cumulative exposures since the biological half-life of Cr in urine is very short (Paustenbach et al. 1997). Most importantly, urinary Cr levels may only represent the total Cr excretion in urine and do not reflect the real exposure or uptake of Cr<sup>VI</sup> due to a number of factors which govern the distribution and excretion of Cr<sup>VI</sup> in the body. In the bloodstream, the absorbed Cr<sup>VI</sup> easily enters into blood cells where Cr<sup>VI</sup> is rapidly reduced into Cr<sup>III</sup> and trapped inside the cells (Ottenwaelde et al. 1988, Coogan et al. 1991, Cohen et al. 1993, Corbett et al. 1998). Therefore, the processes of cellular uptake and intracellular reduction prevent the absorbed Cr<sup>VI</sup> from being excreted in urine except for a portion which has been reduced in plasma before entering the cells. On the other hand, Cr<sup>III</sup> in blood, whether absorbed as such or resulting from Cr<sup>VI</sup> reduction in plasma, can bind to plasma protein and the unbound Cr<sup>III</sup> is rapidly excreted in urine as cell membranes are impermeable to Cr<sup>III</sup> (Christensen 1995, Miksche & Lewalter 1997). Accordingly, urinary Cr seems to only provide information of total extracellular Cr<sup>III</sup> burden with no indication of Cr<sup>VI</sup> uptake. Considering the fact that in cases of Cr<sup>VI</sup> exposure, the Cr<sup>III</sup> excreted in urine is actually the detoxified part, its usefulness for hazard evaluation is limited. For all these reasons, the measurement of urinary Cr was not included in this study.

In conclusion, Cr in RBC may serve as a sensitive and reliable biomarker for long-term occupational, but not environmental, exposure to Cr<sup>VI</sup>. Statistical analyses indicate that age and cigarette smoke are not among the confounders. However, female subjects may have lower Cr in RBC compared with male counterparts at about the same exposure levels. The band III genotype study may suggest a potential

downregulation of  $\text{Cr}^{\text{VI}}$  uptake by erythrocytes in subjects who have either heterozygous or homozygous variant alleles. This potential effect, however, needs to be confirmed.

## Acknowledgements

The authors would like to thank all our Chinese colleagues who participated in this study for their excellent work, and are grateful for the participation of the workers, and the cooperation of management in the Jinan Yuxing Chemical Plant in China. This work was supported by grants R830682 from EPA, ES00260 and ES10344 from NIEHS.

**Declaration of interest:** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

## References

- Alexander J, Aaseth J. 1995. Uptake of chromate in human red blood cells and isolated rat liver cells: the role of the anion carrier. *Analyst* 120:931–933.
- Alper SL. 1991. The band 3-related anion exchanger (AE) gene family. *Annual Review of Physiology* 53:549–564.
- Anderson RA. 1994. Nutritional and toxicologic aspects of chromium intake: an overview. In: Mertz W, Abernathy CO, Olin SS, editors. *Assessment of essential elements*. Washington, DC: ILSI Press. p. 187–196.
- Bruce LJ, Anstee DJ, Spring FA, Tanner MJ. 1994. Band 3 memphis variant II. Altered stilbene disulfonate binding and the diego (dia) blood group antigen are associated with the human erythrocyte band 3 mutation Pro854→Leu. *Journal of Biological Chemistry* 269:16155–16158.
- Bruce LJ, Tanner MJ. 1999. Erythroid band 3 variants and disease. *Baillière's Best Practice & Research. Clinical Haematology* 12:637–654.
- Caglieri A, Goldoni M, Acampa O, Andreoli R, Vettori MV, Corradi M, Apostoli P, Mutti A. 2006. The effect of inhaled chromium on different exhaled breath condensate biomarkers among chrome-plating workers. *Environmental Health Perspectives* 114:542–456.
- Chiu A, Katz AJ, Beaubier J, Chiu N, Shi X. 2004. Genetic and cellular mechanisms in chromium and nickel carcinogenesis considering epidemiologic findings. *Molecular & Cellular Biochemistry* 255:181–194.
- Christensen JM. 1995. Human exposure to toxic metals: factors influencing interpretation of biomonitoring results. *The Science of the Total Environment* 166:89–135.
- Cohen MD, Kargacin B, Klein CB, Costa M. 1993. Mechanisms of chromium carcinogenicity and toxicity. *Critical Reviews in Toxicology* 23:255–281.
- Coogan T, Ssquibb K, Motz J, Kinney P, Costa M. 1991. Distribution of chromium within cells of the blood. *Toxicology and Applied Pharmacology* 108:157–166.
- Corbett GE, Dodge DG, O'Flaherty E, Liang J, Throop L, Finley BL, Kerger BD. 1998. In vitro reduction kinetics of hexavalent chromium in human blood. *Environmental Research* 78:7–11.
- Costa M. 1997. Toxicity and carcinogenicity of  $\text{Cr(VI)}$  in animal models and humans. *Critical Reviews in Toxicology* 27:431–442.
- Davies JM, Easton DF, Bidstrup PL. 1991. Mortality from respiratory cancer and other causes in united kingdom chromate production workers. *British Journal of Industrial Medicine* 48:299–313.
- De Flora S. 2000. Threshold mechanisms and site specificity in chromium(VI) carcinogenesis. *Carcinogenesis* 21:533–541.
- Eller PM, Cassinelli ME. 1994. *NIOSH manual of analytical methods*, 4th ed. Cincinnati, OH: US Department of Health and Human Services, Public Health Service, Centers for Diseases Control and Prevention, National Institute for Occupational Safety and Health.
- Gao M, Levy LS, Braithwaite RA, Brown SS. 1993. Monitoring of total chromium in rat fluids and lymphocytes following intratracheal administration of soluble trivalent or hexavalent chromium compounds. *Human & Experimental Toxicology* 12:377–382.

- Harzendorf C, Lewalter J. 1997. Analytical methodology for biological monitoring of chromium. *Regulatory Toxicology & Pharmacology* 26:S86–S93.
- IARC. 1990. Chromium, nickel and welding. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 49. Lyon: IARC.
- Jarolim P, Rubin HL, Zhai S, Sahr KE, Liu SC, Mueller TJ, Palek J. 1992. Band 3 memphis: a widespread polymorphism with abnormal electrophoretic mobility of erythrocyte band 3 protein caused by substitution AAG---GAG (lys---glu) in codon 56. *Blood* 80:1592–1598.
- Kerger BD, Paustenbach DJ, Corbett GE, Finley BL. 1996. Absorption and elimination of trivalent and hexavalent chromium in humans following ingestion of a bolus dose in drinking water. *Toxicology & Applied Pharmacology* 141:145–158.
- Lukanova A, Toniolo P, Zhitkovich A, Nikolova V, Panev T, Popov T, Taioli E, Costa M. 1996. Occupational exposure to cr(VI): comparison between chromium levels in lymphocytes, erythrocytes, and urine. *International Archives of Occupational & Environmental Health* 69:39–44.
- McAughey JJ, Samuel AM, Baxter PJ, Smith NJ. 1988. Biological monitoring of occupational exposure in the chromate pigment production industry. *Science of the Total Environment* 71:317–322.
- Miksche LW, Lewalter J. 1997. Health surveillance and biological effect monitoring for chromium-exposed workers. *Regulatory Toxicology & Pharmacology* 26:S94–S99.
- Minoia C, Apostoli P, Maranelli G, Baldi C, Pozzoli L, Capodaglio E. 1988. Urinary chromium levels in subjects living in two north Italy regions. *Science of the Total Environment* 71:527–531.
- Moulin JJ, Portefaix P, Wild P, Mur JM, Smaghe G, Mantout B. 1990. Mortality study among workers producing ferroalloys and stainless steel in France. *British Journal of Industrial Medicine* 47:537–543.
- Murgia N, Muzi G, Dell’Omo M, Montuschi P, Melchiorri D, Ciabattini G, Abbritti EP, Orazi N, Sapia IE, Abbritti G. 2006. Induced sputum, exhaled breath condensate and nasal lavage fluid in electroplating workers exposed to chromium. *International Journal of Immunopathology & Pharmacology* 19(4 Suppl.):67–71.
- NRC. 1989. Recommended dietary allowances, 10th ed. National Research Council, Subcommittee on the Tenth Edition of the RDAs, Committee on Dietary Allowances. Washington, DC: National Academy Press.
- Ottenwaelder H, Wiegand HJ, Bolt HM. 1988. Uptake of 51Cr(VI) by human erythrocytes: evidence for a carrier-mediated transport mechanism. *Science of the Total Environment* 71:561–566.
- Palatnik M, Simoes ML, Alves ZM, Laranjeira NS. 1990. The 60 and 63 kDa proteolytic peptides of the red cell membrane band-3 protein: their prevalence in human and non-human primates. *Human Genetics* 86:126–130.
- Paustenbach DJ, Panko JM, Fredrick MM, Finley BL, Proctor DM. 1997. Urinary chromium as a biological marker of environmental exposure: what are the limitations? *Regulatory Toxicology & Pharmacology* 261:S23–S34.
- Wang X, Qin Q, Xu X, Xu J, Wang J, Zhou J, Huang S, Zhai W, Zhou H, Chen J. 1994. Chromium-induced early changes in renal function among ferrochromium-producing workers. *Toxicology* 90:93–101.
- Wiegand HJ, Ottenwalder H, Bolt HM. 1988. Recent advances in biological monitoring of hexavalent chromium compounds. *Science of the Total Environment* 71:309–315.